Breaking Finance News

JP Morgan Cazenove disclosed Shire PLC (LON:SHP), bumping down its price target to 5,300.00GBX earlier today

Boasting a price of 4,057.50GBX, Shire PLC (LON:SHP) traded -0.13% lower on the day. With the last stock price close down -7.64% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Shire PLC has recorded a 50-day average of 3,958.86GBX and a two hundred day average of 4,411.54GBX. Volume of trade was down over the average, with 1,538,848 shares of SHP changing hands under the typical 2,543,530

Reporting a potential upside of 0.31%, JP Morgan Cazenove bumped down the target of Shire PLC (LON:SHP) to 5,300.00GBX

On 08/04/2017, Deutsche Bank released a statement for Shire PLC (LON:SHP) maintained the target price at 6,000.00GBX that suggested an upside of 0.42%.

Performance Chart

Shire PLC (LON:SHP)

With a total market value of 0 GBX, Shire PLC has 52 week low of 3,603.50GBX and a 52 week high of 5,377.00GBX with a P/E ratio of 54.69 .

In addition to JP Morgan Cazenove reporting its stock price target, a total of 18 brokers have issued a report on the company. The average stock price target is 73.73GBX with 6 brokers rating the stock a strong buy, 16 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Shire PLC (LON:SHP)

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *